Brain cancer therapies show promise at SNO meeting
This article was originally published in Scrip
At least four brain cancer therapies and a device showed improvements versus both historical trends in glioblastoma (GBM) and controls during the recent Society for Neuro-Oncology (SNO) annual scientific meeting, including a gene-activated prodrug, an immunotherapy, a hypoxia-targeting agent, an antibody-drug conjugate and a device.
You may also be interested in...
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.